Implantica AG engages in the research and distribution of medical implants in Switzerland. The company’s lead product candidate is RefluxStop, a passive CE-marked implant for prevention of gastroesophageal reflux disease. It is also involved in the development of eHealth platform, a digital health system to support its pipeline of smart medical implants designed for a safe and secure control and monitoring over the internet; e-InVivo, a sensor implants to monitor a multitude of health parameters and provide diagnostic information, as well as control treatment from inside the body; wireless energizing platform; and AppetiteControl, an implant to treat obesity by controlling appetite. In addition, the company develops UriControl, a remote controlled artificial urinary sphincter to treat urinary incontinence for men and women; and UriRestor, a remote-controlled device that enables spinal cord injury and multiple sclerosis patients to urinate on demand using the wireless platform. Further, it provides PotencyFlow for treatment of erectile dysfunction; StomaRestore for eliminating stoma bags; RectalRestore for treatment of fecal incontinence; and AneurysmControl for the treatment of aneurysms. The company was founded in 2015 and is based in Vaduz, Liechtenstein.
Metrics to compare | IMPsdba | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIMPsdbaPeersSector | |
---|---|---|---|---|
P/E Ratio | −34.2x | −2.7x | −0.7x | |
PEG Ratio | 1.41 | −0.11 | 0.00 | |
Price/Book | 7.7x | 2.1x | 2.6x | |
Price / LTM Sales | 421.1x | 2.6x | 3.2x | |
Upside (Analyst Target) | 55.3% | 24.1% | 44.1% | |
Fair Value Upside | Unlock | 4.8% | 8.2% | Unlock |